Cardiovascular disease: Risk factors and applicability of a risk model in a Greek cohort of renal transplant recipients

Table 2 Immunosuppression and cardiovascular disease therapy in all renal transplant recipients and differences between the two groups

	Total RTRs	Group A	Group B	P
Steroids	199 (95.2)	167 (95)	32 (97)	0.61
Mycophenolate mofetil	207 (99)	175 (99.4)	32 (97)	0.18
Tacrolimus	56 (26.8)	49 (27.8)	7 (21.2)	0.43
Cyclosporine	146 (69.9)	122 (69.3)	24 (72.7)	0.69
Everolimus	6 (2.9)	4 (2.3)	2 (6.1)	0.23
CCB	134 (55.4)	116 (56.3)	18 (50)	0.65
Beta-adrenergic blockers	151 (62.4)	128 (62.1)	23 (63.9)	0.86
ARBs/ACEi	131 (54.1)	117 (56.7)	14 (38.9)	0.35
Diuretics	56 (23.1)	46 (21.8)	10 (27.8)	0.58
Other antihypertensive drugs	53 (21.9)	48 (23.3)	5 (13.9)	0.46
Hypolipidemic drugs	154 (63.6)	134 (65)	20 (55.6)	0.49

Immunosuppression therapy was recorded for 209 RTRs. Cardiovascular disease therapy was recorded in all 242 RTRs. Data are expressed as absolute frequency and percentage. Hypolypidemic drugs included statins, fibrates, ezetimibe or combinations of the aforementioned. Group A: With MACE; Group B: Without MACE. MACE: Major advance cardiac event; CCB: Calcium channel blockers; ARBs: Angiotensin receptor blockers; ACEi: Angiotensin converting enzyme inhibitors; RTRs: Renal transplant recipients.